Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 6:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 158 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: quetiapine fumarate Clear all
Completed Phase 4 Interventional

CATIE- Schizophrenia Trial

NCT00014001
View directory record Official record
Conditions
Schizophrenia
Interventions
perphenazine, olanzapine, quetiapine, risperidone, ziprasidone, clozapine, fluphenazine decanoate
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
54
States / cities
Chula Vista, California • Los Angeles, California • Orange, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2015 · Synced Sep 23, 2026, 6:33 AM EDT
Completed Phase 4 Interventional Results available

Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes

NCT00397020
View directory record Official record
Conditions
Bipolar Disorder
Interventions
divalproex ER, quetiapine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Sep 23, 2026, 6:33 AM EDT
Completed Phase 1 Interventional

Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder

NCT02901587
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Lu AF35700 (10 mg/day), Lu AF35700 (30 mg/day), Quetiapine (Seroquel XR® 800 mg/day)
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
21 Years to 60 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 23, 2026, 6:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Efficacy of Quetiapine for Pediatric Delirium

NCT02056171
View directory record Official record
Conditions
Delirium
Interventions
quetiapine, Placebo
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
1 Year to 22 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 23, 2026, 6:33 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Quetiapine Across Pregnancy and Postpartum

NCT02978534
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Quetiapine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Sep 23, 2026, 6:33 AM EDT
Completed Phase 1 Interventional

A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

NCT05542264
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Dayton, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 23, 2026, 6:33 AM EDT
Not listed Not applicable Interventional

Quetiapine for the Treatment of Insomnia in Alzheimer's Disease

NCT00232570
View directory record Official record
Conditions
Alzheimer's Disease, Insomnia
Interventions
quetiapine
Drug
Lead sponsor
University of Vermont
Other
Eligibility
55 Years to 90 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 4, 2009 · Synced Sep 23, 2026, 6:33 AM EDT
Completed Phase 3 Interventional

Quetiapine Fumarate (Seroquel) for the Treatment of Alcohol Dependence.

NCT00124059
View directory record Official record
Conditions
Alcoholism
Interventions
Seroquel, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Sep 23, 2026, 6:33 AM EDT
Completed Phase 2Phase 3 Interventional

Quetiapine in Social Anxiety Disorder

NCT00215254
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
quetiapine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 18, 2006 · Synced Sep 23, 2026, 6:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation

NCT04310579
View directory record Official record
Conditions
Hypercapnia, Ventilatory Depression
Interventions
Oxycodone and Midazolam, Oxycodone, Paroxetine, and Quetiapine
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Sep 23, 2026, 6:33 AM EDT
Completed Phase 3 Interventional

New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia

NCT00161018
View directory record Official record
Conditions
Schizophrenia
Interventions
Quetiapine, Risperidone, Fluphenazine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Sep 23, 2026, 6:33 AM EDT
Terminated Phase 4 Interventional Results available

Gao Bipolar Spectrum Lithium/Quetiapine Study

NCT01526148
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium, Quetiapine
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Sep 23, 2026, 6:33 AM EDT
Completed Phase 4 Interventional Results available

Quetiapine Augmentation for Treatment-resistant PTSD

NCT00292370
View directory record Official record
Conditions
Combat Disorders, Stress Disorders, Post-Traumatic
Interventions
Open Label (OL) Paroxetine, Placebo, Quetiapine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Sep 23, 2026, 6:33 AM EDT
Completed Phase 3 Interventional Results available

Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder

NCT00227305
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder
Interventions
quetiapine fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
31
States / cities
Dothan, Alabama • Scottsdale, Arizona • Cerritos, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Sep 23, 2026, 6:33 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

NCT04373317
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin, Quetiapine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
24
States / cities
Tucson, Arizona • Loma Linda, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 23, 2026, 6:33 AM EDT
Completed Phase 4 Interventional Results available

Seroquel in the Treatment of Dysphoric Hypomania in Bipolar II

NCT00186043
View directory record Official record
Conditions
Bipolar II Disorder
Interventions
Quetiapine/Seroquel, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Sep 23, 2026, 6:33 AM EDT
Completed Not applicable Interventional Results available

Open Label Seroquel (Quetiapine) Study for Treatment Resistant Functional Bowel Disorder

NCT00617396
View directory record Official record
Conditions
Functional Bowel Disorders
Interventions
Quetiapine (50 mg/day-100mg/day)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Sep 23, 2026, 6:33 AM EDT
Completed Phase 2 Interventional Results available

Study of Quetiapine Treatment for Cannabis Dependence

NCT00954681
View directory record Official record
Conditions
Cannabis Dependence
Interventions
quetiapine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 23, 2026, 6:33 AM EDT
Recruiting Phase 4 Interventional

Comparing Antipsychotic Medications in LBD Over Time

NCT05590637
View directory record Official record
Conditions
Parkinson's Disease Psychosis, Dementia With Lewy Bodies
Interventions
Pimavanserin, Quetiapine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 23, 2026, 6:33 AM EDT
Completed Phase 3 Interventional

Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression

NCT00083954
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Quetiapine Fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
36
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Cerritos, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 23, 2026, 6:33 AM EDT
Completed Phase 3 Interventional

Study of Quetiapine Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomanic Symptoms or Mild Manic Symptoms

NCT00277667
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Quetiapine
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Sep 23, 2026, 6:33 AM EDT
Recruiting Phase 2 Interventional

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

NCT06591091
View directory record Official record
Conditions
Depression
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 23, 2026, 6:33 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder

NCT00114686
View directory record Official record
Conditions
Bipolar I Disorder, Alcohol Dependence
Interventions
Quetiapine fumarate, lithium, divalproex
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years to 60 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
38
States / cities
Cerritos, California • San Diego, California • New Haven, Connecticut + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 23, 2026, 6:33 AM EDT
Completed Phase 2 Interventional Results available

A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency

NCT01165541
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Mirtazapine, Quetiapine fumarate extended release (Quetiapine XR)
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Bedford, New Hampshire • Hanover, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 8, 2018 · Synced Sep 23, 2026, 6:33 AM EDT